Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient – Kaiser Health News
Kaiser Health News |
Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
Kaiser Health News Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August. But the total costs of Kymriah and the … Patients could end up paying more than $1M for new gene therapyBecker’s Hospital Review |
|
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Nasdaq SYDNEY, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that new data investigating the use of eftilagimod alpha (IMP321), the Company’s lead product candidate, in combination with … |